All posts by: Michael Zand

About Michael Zand

Novartis’ $8.7bn AveXis deal shows gene therapy appeal – Chemistry World

Continue reading

2018-04-12 NEWS

Novartis’ $8.7bn AveXis deal shows gene therapy appeal
Chemistry World
This is Novartis’ second deal related to an AAV-based gene therapy. In January, it licensed marketing rights for Luxturna from Philadelphia, US-based Spark Therapeutics for $105 million up front and up to $65 million in milestone payments. In December
Worldwide Cancer Gene Therapy Market Overview, Region Wise Analysis of Top Players and Feasibility Studies 2023Pharmaceuticals News
Cancer Gene Therapy Market to Record an Exponential CAGR by 2025The Columnist

all 4 news articles »

Continue reading

2018-04-12 NEWS

Technology Networks

Lonza Opens World’s Largest Dedicated Cell-and-GeneTherapy Manufacturing Facility in Texas
Technology Networks
… committed to the evolution and cultivation of a diverse medical and life-science community in the Greater Houston area for many years to come,” says Marc Funk, Lonza Pharma & Biotech Chief Operating Officer. “The site is well positioned to meet the

Continue reading

2018-04-12 NEWS

STAT

A giant gorilla and a winged wolf: Does ‘Rampage’ get the science of CRISPR right?
STAT
e here at STAT cover CRISPR 1 a lot. But it’s not every day we get to cover Dwayne “The Rock” Johnson. The Rock and the genome-editing technology meet in a new movie, “Rampage 2,” coming out Friday. Through a freak accident, a gorilla, a wolf, and a